These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 11086275)

  • 1. [Activity of new quinolones against clinical isolates of Corynebacterium species].
    Yagüe Guirao G; Martínez-Toldos MC; Mora Peris B; López Domínguez R; Romero Otero M; Muñoz Bellido JL; Segovia Hernández M
    Rev Esp Quimioter; 2000 Sep; 13(3):267-70. PubMed ID: 11086275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activities of new quinolones against coryneform bacteria.
    Martínez-Martínez L; Suárez AI; Ortega MC; Perea EJ
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1439-41. PubMed ID: 8092851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between mutations in the gyrA gene and quinolone resistance in clinical isolates of Corynebacterium striatum and Corynebacterium amycolatum.
    Sierra JM; Martinez-Martinez L; Vázquez F; Giralt E; Vila J
    Antimicrob Agents Chemother; 2005 May; 49(5):1714-9. PubMed ID: 15855486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro activity of levofloxacin, ofloxacin and D-ofloxacin against coryneform bacteria and Listeria monocytogenes.
    Martínez-Martínez L; Pascual A; Suárez AI; Perea EJ
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():27-32. PubMed ID: 10404334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
    Roychoudhury S; Catrenich CE; McIntosh EJ; McKeever HD; Makin KM; Koenigs PM; Ledoussal B
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
    Shultz TR; Tapsall JW; White PA
    Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of linezolid and 12 other antimicrobials against coryneform bacteria.
    Gómez-Garcés JL; Alos JI; Tamayo J
    Int J Antimicrob Agents; 2007 Jun; 29(6):688-92. PubMed ID: 17475450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of tigecycline and 10 other antimicrobials against clinical isolates of the genus Corynebacterium.
    Fernandez-Roblas R; Adames H; Martín-de-Hijas NZ; Almeida DG; Gadea I; Esteban J
    Int J Antimicrob Agents; 2009 May; 33(5):453-5. PubMed ID: 19153032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of 11 fluoroquinolones against 226 Campylobacter jejuni strains isolated from Finnish patients, with special reference to ciprofloxacin resistance.
    Lehtopolku M; Hakanen AJ; Siitonen A; Huovinen P; Kotilainen P
    J Antimicrob Chemother; 2005 Dec; 56(6):1134-8. PubMed ID: 16223936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of eight fluoroquinolones against multiresistant Stenotrophomonas maltophilia.
    Sánchez-Hernández J; Manzanares MA; Gutiérrez Zufiaurre MN; Muñoz Criado S; Muñoz Bellido JL; García-Rodríguez JA
    Rev Esp Quimioter; 1999 Sep; 12(3):234-6. PubMed ID: 10878514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of ciprofloxacin, moxifloxacin, vancomycin and erythromycin against planktonic and biofilm forms of Corynebacterium urealyticum.
    Soriano F; Huelves L; Naves P; Rodríguez-Cerrato V; del Prado G; Ruiz V; Ponte C
    J Antimicrob Chemother; 2009 Feb; 63(2):353-6. PubMed ID: 19056748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates.
    Adam HJ; Schurek KN; Decorby MR; Weshnoweski B; Vashisht R; Karlowsky K; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2006 Jul; 58(1):202-4. PubMed ID: 16636082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S; Ianniello F; Leone S; Esposito S
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of macrolide resistance mechanisms in clinical isolates of Corynebacterium species.
    Ortiz-Pérez A; Martín-de-Hijas NZ; Esteban J; Fernández-Natal MI; García-Cía JI; Fernández-Roblas R
    Microb Drug Resist; 2010 Dec; 16(4):273-7. PubMed ID: 20624090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative antianaerobic activity of BMS 284756.
    Hoellman DB; Kelly LM; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2001 Feb; 45(2):589-92. PubMed ID: 11158759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activities of gemifloxacin and five other antimicrobial agents against Listeria monocytogenes and coryneform bacteria isolated from clinical samples.
    Martínez-Martínez L; Joyanes P; Suárez AI; Perea EJ
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2390-2. PubMed ID: 11451706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of newer antibiotics against Corynebacterium jeikeium, Corynebacterium amycolatum and Corynebacterium urealyticum.
    Sánchez Hernández J; Mora Peris B; Yagüe Guirao G; Gutiérrez Zufiaurre N; Muñoz Bellido JL; Segovia Hernández M; García Rodríguez JA
    Int J Antimicrob Agents; 2003 Nov; 22(5):492-6. PubMed ID: 14602367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing.
    Stout JE; Sens K; Mietzner S; Obman A; Yu VL
    Int J Antimicrob Agents; 2005 Apr; 25(4):302-7. PubMed ID: 15784309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.